Search results for "FOSB"

showing 10 items of 42 documents

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrho…

2018

Background: In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this “real-life” study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV). Methods: All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV+SOF±RBV for 24 weeks; sustained virological response was assessed at 12 weeks post-treatment (SVR12). Results: Eighty-seven patients were enrolled (75.9% males, mean age 58.4 ±…

Liver CirrhosisMalehepatitis C virusPyrrolidinesCirrhosisSofosbuvirmedicine.medical_treatmentantiviral treatmentHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrencehepatitis C viruProspective StudiesProspective cohort studySettore MED/12 - Gastroenterologialiver transplantationdirect antiviral agentsImidazolesValineHepatitis CMiddle AgedPrognosisHepatitis CItalyHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyDaclatasvirHepatitis C virusAntiviral Agentsantiviral treatment; cirrhosis; direct antiviral agents; hepatitis C virus; liver transplantation03 medical and health sciencesInternal medicineRibavirinmedicineHumansTransplantationdirect antiviral agentbusiness.industryRibavirincirrhosismedicine.diseasechemistryCarbamatesSofosbuvirbusinessFollow-Up Studiescirrhosi
researchProduct

Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy

2019

Background & Aims: In patients with hepatitis C virus (HCV)-related advanced cirrhosis, the effects of sustained virological response (SVR) by direct antiviral agents (DAAs) on decompensation and liver deaths are less clearcut, since up to 30% of patients do not improve, and no predictors of outcome have been identified. We used 13C-aminopyrine breath test (ABT) to assess whether its changes can predict liver-related outcomes after DAA treatment in patients with HCV cirrhosis. Methods: Fifty consecutive patients with HCV cirrhosis were enrolled. Patients were included if they had Child A cirrhosis at risk for decompensation – defined as Child A6 (N = 22, 44%) or previous decompensation …

Liver Cirrhosismedicine.medical_specialtyCirrhosisSofosbuvirHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsGastroenterologyInternal medicineHumansMedicineDecompensationAminopyrineChildCIRRHOSISHepatic encephalopathyaminopyrine breath testBreath testHepatologymedicine.diagnostic_testdirect antiviral agentCumulative dosebusiness.industryHepatitis C Chronicmedicine.diseaseHepatitis CBreath Testsliver functionLiver functionbusinessDIRECT ANTIVIRAL AGENTSAMINOPYRINE BREATH TEST; CIRRHOSIS; DIRECT ANTIVIRAL AGENTS; LIVER FUNCTIONmedicine.drugcirrhosi
researchProduct

Involvement of TLR4 in the long-term epigenetic changes, rewarding and anxiety effects induced by intermittent ethanol treatment in adolescence

2016

Studies in humans and experimental animals have demonstrated the vulnerability of the adolescent brain to actions of ethanol and the long-term consequences of binge drinking, including the behavioral and cognitive deficits that result from alcohol neurotoxicity, and increased risk to alcohol abuse and dependence. Although the mechanisms that participate in these effects are largely unknown, we have shown that ethanol by activating innate immune receptors, toll-like receptor 4 (TLR4), induces neuroinflammation, impairs myelin proteins and causes cognitive dysfunctions in adolescent mice. Since neuroimmune signaling is also involved in alcohol abuse, the aim of this study was to assess whethe…

Male0301 basic medicineEpigenetic changesmedia_common.quotation_subjectImmunologyRewarding effectsAlcohol abuseBinge drinkingAnxietyBinge DrinkingEpigenesis GeneticMice03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineRewardNeuroimmune systemmedicineAnimalsTLR4Neuroinflammationmedia_commonMice KnockoutEthanolBinge ethanol treatmentEndocrine and Autonomic SystemsAddictionAge FactorsNeurotoxicityBrainAnxiety-like behaviormedicine.diseaseEthanol preferencePrelimbic medial prefrontal cortexAdolescenceMice Inbred C57BLToll-Like Receptor 4Alcoholism030104 developmental biologySynaptic plasticityFemaleCognition DisordersPsychologyNeuroscienceMyelin Proteins030217 neurology & neurosurgeryFOSBBrain, Behavior, and Immunity
researchProduct

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

2018

AbstractNatural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mai…

Male0301 basic medicineSofosbuvirHepacivirusDrug Resistancelcsh:MedicineHepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyHepatitis C Virus; HCV resistance-testchemistry.chemical_compound0302 clinical medicineGenotypePrevalenceVirallcsh:ScienceHCV resistance-testMultidisciplinarybiologyHepatitis CMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCohortHCVFemale030211 gastroenterology & hepatologymedicine.drugAdultmedicine.medical_specialtyHepatitis C VirusGenotypeHCV RASHepatitis C virus03 medical and health sciencesInternal medicineDrug Resistance ViralmedicineHumansAdult; Aged; Drug Resistance Viral; Female; Hepacivirus; Hepatitis C; Humans; Italy; Male; Middle Aged; Prevalence; Viral Nonstructural Proteins; GenotypeNS5ANS5BAgedbusiness.industrylcsh:RHepatitis C Virus HCV resistance-testbiology.organism_classificationmedicine.disease030104 developmental biologychemistrylcsh:Qbusiness
researchProduct

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

2017

Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and w…

Male0301 basic medicinehepatitis C virusSustained Virologic ResponseSofosbuvirHepacivirusDrug ResistanceHepacivirusresistance-associated substitutionsViral Nonstructural ProteinsVARIANTSNS5Amedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrenceINFECTIONantiviral therapyMedicinehepatitis C viruViralTreatment FailureChronicantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; hepatologybiologyGENOTYPE 1virus diseasesMiddle Agedantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutionsSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCombinationInterferonDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAuthor Keywords:antiviral therapyRIBAVIRINSequence AnalysisHumanmedicine.drugmedicine.medical_specialtyDaclatasvirGenotypeHepatitis C virusAntiviral AgentsLONG-TERM PERSISTENCEDACLATASVIR03 medical and health sciencesDrug Therapyantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; Aged; Antiviral Agents; Drug Resistance Viral; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; HepatologyTREATMENT-NAIVEInternal medicineDrug Resistance ViralRibavirinHumansNS5Aresistance testdirect-acting antiviralsAgedAntiviral Agentresistance-associated substitutiondirect-acting antiviralHepaciviruHepatologyresistance test KeyWords Plus:HEPATITIS-C VIRUSbusiness.industryRibavirinViral Nonstructural ProteinSequence Analysis DNADNAHepatitis C ChronicHepatologybiology.organism_classificationClinical trial030104 developmental biologySOFOSBUVIRchemistrySequence AnalysihepatologyMutationImmunologyInterferonsSofosbuvirbusiness
researchProduct

A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.

2016

The objective of this study was to compare the efficacy of sofosbuvir-based treatments in patients with chronic hepatitis C virus (HCV) infection using a model-based meta-analysis (MBMA). A bibliographic search was performed to identify clinical trials involving sofosbuvir as a unique direct-acting antiviral (DAA) agent or together with daclatasvir, ledipasvir or simeprevir for the treatment of diagnosed HCV infection. The time course of the virological response (VR) was modelled to estimate the effect of treatment and the influence of population characteristics on the longitudinal efficacy profile. The model was validated and simulations of 10 different treatment schedules were performed. …

MaleMicrobiology (medical)OncologyLedipasvirSimeprevirmedicine.medical_specialtyPyrrolidinesDaclatasvirSofosbuvirHepatitis C virusPopulationHepacivirusPharmacologymedicine.disease_causeAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSimeprevirInternal medicinemedicineHepatitis C virus Meta-analysis Modelling Simulation SofosbuvirHumansPharmacology (medical)030212 general & internal medicineeducationFluoreneseducation.field_of_studybusiness.industryImidazolesValineGeneral MedicineHepatitis C ChronicModels TheoreticalClinical trialInfectious DiseaseschemistryMeta-analysisBenzimidazolesDrug Therapy CombinationFemale030211 gastroenterology & hepatologyCarbamatesSofosbuvirbusinessmedicine.drug
researchProduct

Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

2021

Aim: This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3). Methods: Within the Italian VIRONET-C network, a total of 539 GT3-infected patients (417 DAA-naïve and 135 DAA-failures, of them, 13 at both baseline and failure) were analysed. Sanger sequencing of NS3/NS5A/NS5B was performed following home-made protocols. Results: The majority of patients were male (79.4%), 91.4% were injection drug users, 49.3% were cirrhotic and 13.9% were HIV co-infected. Phylogenetic analysis classified sequences as GT3a-b-g-h (98%-0.4%-0.2%-1.2%) respectively. Overall, 135 patients failed a DAA regimen: sofosbuvir (SO…

MaleSofosbuvirSustained Virologic ResponseDrug ResistanceHepacivirusViral Nonstructural ProteinsGastroenterologySettore MED/06direct-acting antivirals; failure; genotype 3; HCV; resistancechemistry.chemical_compound0302 clinical medicineMedicineViralChronicPhylogenyDasabuvirdirect-acting antivirals; failure; genotype 3; hcv; resistancevirus diseasesHepatitis CPibrentasvirfailureItaly030220 oncology & carcinogenesisHCVCombinationDrug Therapy Combination030211 gastroenterology & hepatologyFemalemedicine.drugLedipasvirmedicine.medical_specialtyDaclatasvirGenotypedirect-acting antivirals; failure; genotype 3; HCV; resistance; Antiviral Agents; Drug Resistance Viral; Drug Therapy Combination; Female; Genotype; Humans; Italy; Male; Phylogeny; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins; Hepacivirus; Hepatitis C ChronicAntiviral Agentsresistance03 medical and health sciencesDrug TherapyInternal medicineDrug Resistance ViralHumansgenotype 3direct-acting antiviralsAntiviral Agentdirect-acting antiviralHepaciviruHepatologybusiness.industryViral Nonstructural ProteinGlecaprevirHepatitis C ChronicHCV; direct acting antivirals; failure; genotype 3; resistanceRegimenchemistryParitaprevirSofosbuvirbusinessHepatitis C Chronic.
researchProduct

Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Respons…

2015

UNLABELLED Although sofosbuvir has been approved for patients with genotypes 2/3 (G2/3), many parts of the world still consider pegylated Interferon alpha (P) and ribavirin (R) as standard of care for G2/3. Patients with rapid virological response (RVR) show response rates >80%. However, SVR (sustained virological response) in non-RVR patients is not satisfactory. Longer treatment duration may be required but evidence from prospective trials are lacking. A total of 1006 chronic HCV genotype 2/3 patients treated with P/R were recruited into a German HepNet multicenter screening registry. Of those, only 226 patients were still HCV RNA positive at week 4 (non-RVR). Non-RVR patients with ongoin…

Malemedicine.medical_specialtyGenotypeSofosbuvirlcsh:MedicineAlpha interferonHepaciviruslaw.inventionchemistry.chemical_compoundRandomized controlled trialRecurrencelawPegylated interferonSurveys and QuestionnairesInternal medicineRibavirinClinical endpointmedicineHumansProspective Studiesddc:610lcsh:ScienceProspective cohort studyMultidisciplinarybusiness.industryRibavirinlcsh:RInterferon-alphaHepatitis C ChronicMiddle AgedSurgeryClinical trialLogistic ModelsTreatment OutcomechemistryMultivariate AnalysisFemalelcsh:QbusinessResearch Articlemedicine.drugPLOS ONE
researchProduct

Changes in histone acetylation in the prefrontal cortex of ethanol-exposed adolescent rats are associated with ethanol-induced place conditioning

2012

Alcohol drinking during adolescence can induce long-lasting effects on the motivation to consume alcohol. Abnormal plasticity in reward-related processes might contribute to the vulnerability of adolescents to drug addiction. We have shown that binge-like ethanol treatment in adolescent rats induces alterations in the dopaminergic system and causes histone modifications in brain reward regions. Considering that histone acetylation regulates transcriptional activity and contributes to drug-induced alterations in gene expression and behavior, we addressed the hypothesis that ethanol is capable of inducing transcriptional changes by histone modifications in specific gene promoters in adolescen…

Malemedicine.medical_specialtyPrefrontal CortexHDAC inhibitionChromatin remodelingHistonesCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicineConditioning PsychologicalmedicineAnimalsEpigeneticsRats WistarConditioned place aversionPharmacologyEthanolbiologyHistone modificationsAge FactorsAcetylationSodium butyrateRatsAdolescenceHistone Deacetylase InhibitorsHistoneEndocrinologychemistryBiochemistryAcetylationbiology.proteinBrain stimulation rewardBinge-like ethanol treatmentHistone deacetylaseFOSBNeuropharmacology
researchProduct

Hypertrophic agonists induce the binding of c-Fos to an AP-1 site in cardiac myocytes: implications for the expression of GLUT1

2003

Objectives: Serum is among the agents known to induce hypertrophy of cardiac myocytes, which occurs concomitant with an increase in AP-1-mediated transcription. We have examined if this effect correlates with changes in the relative abundance of particular AP-1 heterodimers, as their exact composition under these conditions is unknown. Furthermore, we obtained insight on the specific role of c-Fos from studying the induction of the glucose transporter GLUT1 by serum in fibroblasts. Methods: We characterised the AP-1 heterodimers expressed in neonatal cardiac myocytes by supershift electrophoretic mobility shift assay (EMSA) analysis. Quantitative changes in transcription were measured using…

Monosaccharide Transport ProteinsTranscription GeneticMAP Kinase Signaling SystemPyridinesPhysiologyJUNBBlotting WesternElectrophoretic Mobility Shift Assayc-FosCell LineMicePhysiology (medical)Gene expressionAnimalsMyocyteMyocytes CardiacElectrophoretic mobility shift assayCells CulturedFlavonoidsGlucose Transporter Type 1biologyImidazolesGlucose transporterFibroblastsMolecular biologyRatsEnzyme ActivationTranscription Factor AP-1Animals Newbornbiology.proteinGLUT1Mitogen-Activated Protein KinasesCardiology and Cardiovascular MedicineProto-Oncogene Proteins c-fosGene DeletionProtein BindingFOSBCardiovascular Research
researchProduct